Arquivos do dia: Fevereiro 17, 2022

Estudo randomizado | Nirmatrelvir oral para adultos de alto risco com Covid-19 reduz em 89% o risco de internação.

17 Fev, 2022 | 15:37h

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 – New England Journal of Medicine

Entrevista em áudio: A New Antiviral against Covid-19 – new England Journal of Medicine

Conteúdos relacionados:

[Press release – not published yet] Pfizer’s Covid pill remains 89% effective for reducing the risk of hospitalization or death in final analysis.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

Statement on potential drug-drug interactions between Ritonavir-boosted Nirmatrelvir (Paxlovid) and concomitant medications; antiarrhythmics, oral anticoagulants, immunosuppressants, anticonvulsants, antineoplastics, and neuropsychiatric drugs are among the drugs of concern.

 

Comentário no Twitter

The Paxlovid pill (Nirmatrelvir) randomized, placebo-controlled trial published @NEJM:
89% efficacy vs Covid hospitalizations or deaths, and quick reduction of viral load.
The active pills had less serious adverse events or discontinuations than placebohttps://t.co/HBMRZt4wBo pic.twitter.com/LDQv41O56c

— Eric Topol (@EricTopol) February 16, 2022

 

---

Estudo de coorte retrospectiva | Vacina da Pfizer reduz o risco de reinfecção após recuperação da Covid-19.

17 Fev, 2022 | 15:35h

Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19 – New England Journal of Medicine

 

Comentário no Twitter

Among patients who had recovered from Covid-19, the receipt of at least one dose of the BNT162b2 vaccine was associated with a significantly lower risk of recurrent infection. https://t.co/AAlsY9sFlv pic.twitter.com/Nkj1lP77ZW

— NEJM (@NEJM) February 16, 2022

 

---

Estudo de coorte | Proteção contra SARS-CoV-2 após vacinação para Covid-19 dura mais em pacientes com infecção prévia.

17 Fev, 2022 | 15:34h

Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection – New England Journal of Medicine

---

Inglaterra vai oferecer doses de vacina contra Covid para crianças de 5 a 11 anos de idade.

17 Fev, 2022 | 15:32h

England to offer Covid jab to five to 11-year-olds – BBC

---

Metanálise mostra que a prevalência geral de intolerância à estatina é de cerca de 9% e identifica os fatores de risco mais comuns.

17 Fev, 2022 | 15:31h

Prevalence of statin intolerance: a meta-analysis – European Heart Journal

Comentários:

Study shows the true prevalence of statin intolerance worldwide is between 6 to 10% – News Medical / European Society of Cardiology

Expert reaction to study looking at statin intolerance – Science Media Centre

Conteúdos relacionados:

Side effect patterns in a crossover trial of statin, placebo, and no treatment – This N-of-1 trial, now published in full, suggests the nocebo effect causes most of statins muscle adverse effects.

#AHA20 – In patients who had discontinued statins because of side effects, a N-of-1 trial of a statin, placebo, or no treatment found that side effects often attributed to statins were the same for those taking a placebo

 

Comentário no Twitter

Statin intolerance is “over-estimated and over-diagnosed”. World’s largest study shows less than 10% suffer side-effects caused by statins https://t.co/pcVk8YI3I3@escardio #EHJ #ESCYoung #cardiotwitter @ehj_ed @rladeiraslopes #CVD #Riskfactors pic.twitter.com/b3nFWsc74d

— European Society of Cardiology Journals (@ESC_Journals) February 16, 2022

 

---

Revisão | Diagnóstico e tratamento de síndromes coronarianas agudas.

17 Fev, 2022 | 15:29h

Diagnosis and Treatment of Acute Coronary Syndromes: A Review – JAMA (gratuito por tempo limitado)

Revisão clínica em áudio: Diagnosis and Treatment of Acute Coronary Syndromes – JAMA

---

Posicionamento científico SIMEU sobre suporte respiratório não invasivo na pneumonia por COVID-19.

17 Fev, 2022 | 15:28h

SIMEU position paper on non-invasive respiratory support in COVID-19 pneumonia – Internal and Emergency Medicine

Conteúdos relacionados:

RCT: CPAP improved outcomes in patients with acute hypoxemic respiratory failure due to COVID-19, but high-flow nasal oxygen was not better than conventional oxygen therapy.

RCT: In patients with severe Covid-19, high-flow oxygen therapy reduced the likelihood of invasive mechanical ventilation and decreased the time to clinical recovery compared to conventional oxygen therapy.

Non-invasive respiratory support in the management of acute COVID-19 pneumonia: considerations for clinical practice and priorities for research – “The two randomized controlled trials indicate superiority of non-invasive ventilation over high-flow nasal oxygen in reducing the need for intubation”.

---

Fatores de risco para admissão em UTI pediátrica e morte entre crianças e jovens internados com COVID-19 e síndrome inflamatória multissistêmica pediátrica temporariamente relacionada ao SARS-CoV-2 (pediatric inflammatory multi-system syndrome temporally associated with SARS-CoV-2 – PIMS-TS).

17 Fev, 2022 | 15:25h

Risk factors for PICU admission and death among children and young people hospitalized with COVID-19 and PIMS-TS in England during the first pandemic year – Nature Medicine

Comentário: Studies detail risk of severe COVID-19, GI problems in kids – CIDRAP

 

Comentário no Twitter

The risk of intensive care unit admission among children with COVID-19 is affected by age, ethnicity and comorbidities, according to a @NatureMedicine paper. Understanding these modifiers might help identify at-risk children and guide interventions. https://t.co/MIkLecyNI6 pic.twitter.com/JtN3Ab4Lu7

— Nature Portfolio (@NaturePortfolio) December 20, 2021

 

---

Como a COVID-19 transformou a genômica e mudou para sempre o tratamento de surtos de doenças.

17 Fev, 2022 | 15:24h

How COVID-19 transformed genomics and changed the handling of disease outbreaks forever – The Conversation

---

Revisão | Infraestrutura da rede de esgoto na saúde pública: aplicações e aprendizados da pandemia de COVID-19.

17 Fev, 2022 | 15:22h

Wastewater network infrastructure in public health: Applications and learnings from the COVID-19 pandemic – PLOS Global Public Health

Conteúdo relacionado:

Opinion: Wastewater analysis can be a powerful public health tool—if it’s done sensibly.

CDC unveils its latest weapon in Covid-19 detection: wastewater.

CDC Report: Using Wastewater Surveillance Data to Support the COVID-19 Response — United States, 2020–2021.

Rapid, large-scale wastewater surveillance and automated reporting system enabled early detection of nearly 85% of COVID-19 cases on a University campus.

[Preprint] Wastewater genomic testing can effectively track COVID-19 variants of concern.

Human Waste Could Be The Next Big Weapon in Controlling COVID-19 – TIME

Next steps for wastewater testing to help end this pandemic — and prevent the next one – STAT

Sewage sleuths helped an Arizona town beat back Covid-19. For wastewater epidemiology, that’s just the start – STAT

The myriad ways sewage surveillance is helping fight COVID around the world – Nature

Testing sewage can give school districts, campuses and businesses a heads-up on the spread of COVID-19 – The Conversation

It’s time to begin a national wastewater testing program for Covid-19 – STAT

Coronavirus: Testing sewage an ‘easy win’ – BBC

Development of wastewater pooled surveillance of SARS-CoV-2 from congregate living settings – high sensitivity, but unable to distinguish new infectious cases from persistent convalescent shedding.

---